Bulbar involvement in patients with antiganglioside antibodies against NeuNAc(alpha 2-3) Gal


Por: Rojas-Garcia, R, Gallardo, E, De Luna, N, Juarez, C, Martinez-Hernandez, E, Carvajal, A, Casasnovas, C, Fages, E, Davila-Gonzalez, P, Illa, I

Publicada: 1 jun 2010
Resumen:
Background Reactivity against terminal NeuNAc(alpha 2-3) Gal, common to several gangliosides such as GD1a, GT1b and GM3, has rarely been reported. The authors recently described a patient with a clinical picture of acute relapsing sensory ataxic neuropathy and bulbar involvement in whom they demonstrated concomitant reactivity against NeuNAc(alpha 2-3) Gal and disialosyl epitopes. The authors suggested a correlation between NeuNAc(alpha 2-3) Gal reactivity and bulbar involvement. Aim To determine the frequency of reactivity against terminal NeuNAc(alpha 2-3) Gal in acute and chronic immune-mediated disorders, and its possible correlation with bulbar involvement. Methods The authors retrospectively reviewed reactivity in the serum of more than 3000 consecutive patients with acute and chronic disorders in which antiganglioside antibodies were studied. The authors selected those patients who were simultaneously positive, by ELISA or thin-layer chromatography, for IgG or IgM antibodies anti-GM3, GD1a and GT1b, and reviewed their clinical features. Results Reactivity against NeuNAc(alpha 2-3) Gal, shared by GM3, GD1a and GT1b gangliosides, was detected in 10 patients: isolated in one patient, and concomitant with reactivity against other gangliosides in the remaining patients. Reactivity against NeuNAc(alpha 2-3) Gal was frequently associated (8/10) with symptoms suggestive of bulbar involvement, such as dysphagia, dysarthria or dysphonia. Severe respiratory failure requiring mechanical ventilation was observed in four patients. Conclusions Reactivity against the NeuNAc(alpha 2-3) Gal epitope is rare and is generally found in association with reactivity against the disialosyl epitope. It can be detected in patients with acute or chronic disorders and could be a serological marker of clinical bulbar involvement and, to a lesser extent, associated with the development of severe respiratory failure.

Filiaciones:
Rojas-Garcia, R:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, Neuromuscular Dis Unit, Barcelona 08025, Spain

 CIBERNED, Seville, Spain

Gallardo, E:
 CIBERNED, Seville, Spain

 Hosp Santa Creu & Sant Pau, Inst Recerca, Lab Expt Neurol, Barcelona, Spain

De Luna, N:
 CIBERNED, Seville, Spain

 Hosp Santa Creu & Sant Pau, Inst Recerca, Lab Expt Neurol, Barcelona, Spain

Juarez, C:
 Hosp Santa Creu & Sant Pau, Dept Immunol, Barcelona, Spain

Martinez-Hernandez, E:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, Neuromuscular Dis Unit, Barcelona 08025, Spain

 CIBERNED, Seville, Spain

Carvajal, A:
 Hosp Sierrallana, Dept Neurol, Torrelavega, Spain

Casasnovas, C:
 Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge, Dept Neurol, Lhospitalet De Llobregat, Spain

Fages, E:
 Hosp Santa Maria Rosell, Dept Neurol, Cartagena, Spain

Davila-Gonzalez, P:
 Hosp Manacor, Dept Neurol, Manacor, Spain

Illa, I:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, Neuromuscular Dis Unit, Barcelona 08025, Spain

 CIBERNED, Seville, Spain
ISSN: 00223050





JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Editorial
BMJ PUBLISHING GROUP, BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 81 Número: 6
Páginas: 623-628
WOS Id: 000278354100010
ID de PubMed: 19726412

MÉTRICAS